United Kingdom Primary Cells Market Size, Share, and COVID-19 Impact Analysis, By Origin (Human, Animal), By Application (Regenerative Medicine, Drug Discovery and Development, Regenerative Medicine, Cancer Research, and Others), and United Kingdom Primary Cells Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Primary Cells Market Insights Forecasts to 2035

• The United Kingdom Primary Cells Market Size was Estimated at USD 115.45 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.30% from 2025 to 2035
• The United Kingdom Primary Cells Market Size is Expected to Reach USD 277.58 Million by 2035

According to a research report published by Spherical Insights and Consulting, The United Kingdom Primary Cells Market Size is anticipated to reach USD 277.58 Million by 2035, growing at a CAGR of 8.30% from 2025 to 2035. The expanding need for monoclonal antibodies, the growing number of pharmaceutical and biotechnology firms, the growing benefits of primary human cells over cell lines, and the growing government programs for cell-based research are all factors contributing to this growth.

Market Overview

The United Kingdom primary cells market refers to the industry focused on the cells extracted directly from the living tissues of animals or humans, which are then processed for use in various applications. These cells are widely used in biomedical research, drug discovery, regenerative medicine, and cell therapy. The high level of innovation is brought forth by both the growing need for more dependable cellular models in biological research and technological breakthroughs. The biomedical sector is making significant strides because of continuous improvements in quality control procedures, preservation strategies, and cell separation techniques. These developments are making primary cells more precise and physiologically relevant models for researching human biology and illness, which will ultimately improve patient outcomes. Additionally, combining them with cutting-edge technologies like 3D bioprinting and organ-on-a-chip systems has enormous potential to advance personalized medicine, toxicological screening, and drug development. Recently, the UK Regenerative Medicine Platform (UKRMP) was a £42 million national initiative established in 2013 by BBSRC, EPSRC, and MRC to support regenerative medicine research and address key translational challenges. Cancer Research UK allocates a significant portion of its funding to cancer research, with around 40% focused on basic laboratory research into the molecular basis of cancer.

Report Coverage

This research report categorizes the market for the United Kingdom primary cells market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom primary cells market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom primary cells market.

Driving Factors

The market for United Kingdom primary cells is driven by the country's explosive growth of the healthcare sector, with high-skilled professionals. Besides, key businesses are concentrating on expanding in a variety of geographic areas by carefully enhancing their portfolios and raising production capacity. Furthermore, the growing need for therapeutic antibodies to treat chronic illnesses speeds up cellular and molecular biology research and development, expanding these businesses' product lines. Additionally, the use of cutting-edge preclinical technologies like 3D cell cultures, which use patient-derived material, is driving the primary cell market. This pattern encourages the creation of novel therapies and methods in the domain. at the moment.

Restraining Factors

However, in primary cell cultures, contamination is a serious problem since it can increase variability, have a detrimental effect on experimental outcomes, and undermine the validity of study findings. The main issues with primary cell culture contamination are cross-contamination, mycoplasma contamination, virus contamination, and bacterial and fungal contamination.

Market Segmentation

The United Kingdom Primary Cells Market share is classified into origin, and application.

• The human segment accounted for the largest market share in 2024 and is anticipated to grow at a substantial CAGR over the forecast period.

The United Kingdom primary cells market is divided by origin into human and animal. Among these, the human segment accounted for the largest market share in 2024 and is anticipated to grow at a substantial CAGR over the forecast period. They are crucial for research and development because, unlike immortalized cell lines, they closely mimic the physiological condition of cells in vivo, yielding more physiologically meaningful data. The physiological significance of the data produced is greatly increased by their incorporation into cell culture systems, which allows researchers to get important insights that are more in line with in vivo results.

• The regenerative medicine segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period.

The United Kingdom primary cells market is segmented by application into regenerative medicine, drug discovery and development, regenerative medicine, cancer research, and others. Among these, the regenerative medicine segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period. This is because human basic cells closely resemble the biology of cells in vivo, and they are important in regenerative medicine. Isolated directly from human tissues, these cells offer a more accurate and pertinent depiction of human biology than immortalized cell lines.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom primary cells market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Oxford Biomedica
• Quell Therapeutics Ltd
• Amphista Therapeutics
• GSK (GlaxoSmithKline)
• AstraZeneca
• Others

Recent Developments:

• In June 2025, the collaborated between MaxCyte and Ori Biotech relevant to the UK market for primary cells. The partnership aimed to improve manufacturing efficiencies and broaden the adoption of autologous cellular therapies, specifically focusing on gene-edited T cells. Since Ori Biotech was based in London, UK, and the collaboration involved optimizing cell therapy manufacturing processes, it contributed to advancements in the field.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom primary cells market based on the below-mentioned segments:

United Kingdom Primary Cells Market, By Origin

• Human
• Animal

United Kingdom Primary Cells Market, By Application

• Regenerative Medicine
• Drug Discovery and Development
• Regenerative Medicine
• Cancer Research
• Others